Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

Phase 1 Completed 21 enrolled Amgen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma.

Timeline

Start: 2012-11
Primary completion: 2013-08
Completion: 2015-03

Publications

Doi T, Yamaguchi K, Komatsu Y, Muro K, Nishina T, Nakajima TE, Tang R, Yang H, Zhang Y, Jung AS, Ang A, Yasui H. A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. Jpn J Clin Oncol. 2017 Nov 1;47(11):1002-1009. doi: 10.1093/jjco/hyx114.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rilotumumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Rilotumumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Rilotumumab	Monoclonal antibody	20 mg/kg	Intravenous

Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

Summary

Timeline

Publications

Drugs

Indications